Core Insights - SBC Medical Group Holdings Incorporated reported significant improvements in profitability for Q4 2025, with EPS more than doubling to $0.14, reflecting a 133% year-over-year increase [1][4] - The company experienced a decline in total revenues for both Q4 and full year 2025, attributed to structural changes and franchise fee revisions [5][10] Q4 2025 Highlights - Total revenues for Q4 2025 were $40 million, an 11% decrease year-over-year [4] - Net income attributable to SBC Medical Group was $14 million, a 117% increase year-over-year [4] - EBITDA for Q4 was $14 million, representing a 35% decrease year-over-year, with an EBITDA margin of 34%, down 12 percentage points [4] - The number of franchise locations increased to 283, up by 34 from the previous year [4] - Customer count reached 6.6 million, a 12% increase year-over-year, with a repeat customer rate of 72% [4] Full Year 2025 Highlights - Total revenues for the full year were $174 million, a 15% decrease year-over-year [10] - Net income attributable to SBC Medical Group grew 9% to $51 million, with an EPS of $0.50, a 4% increase year-over-year [10][6] - The net income margin expanded from 23% to 29%, while the EBITDA margin normalized from 43% to 40% [6] - Average revenue per customer increased to $316, an 11% year-over-year rise [7] Strategic Focus for 2026 - The company aims to advance its multi-brand strategy in dermatology, expand its non-aesthetic healthcare portfolio, and strengthen its international market presence [8]

Financial Data and Key Metrics Changes - Revenues for the March quarter were $232 million, a 12% increase from $207 million in the same quarter last year [4][14] - Earnings per share (EPS) for the quarter were $0.51, a 38% increase from $0.37 in the same quarter of the prior year [4][14] - Revenues for the fiscal year 2025 were $896 million, up 13% from $795 million in the prior fiscal year [4][14] - EPS for the fiscal year was $1.83, a 24% increase compared to $1.47 for the fiscal year ended March 2024 [4][14] - Gross profit for the March quarter increased by 5% year-over-year [15] Business Line Data and Key Metrics Changes - Patient management revenue for the March quarter was $149 million, an increase of 6% [14] - Patient management revenue for the fiscal year was $581 million, an annual increase of 10% [15] - Network solutions revenue for the March quarter was $83 million, up 24% from the same quarter of the prior year [17] - Network solutions revenue for the fiscal year was $314 million, an annual increase of 19% [18] - Gross profit in the wholesale business was up 71% from the March quarter of the prior year [18] Market Data and Key Metrics Changes - The company noted ongoing shifts in trade dynamics that could present longer-term opportunities, particularly in reshoring manufacturing and supply chain operations [5] - Increased claims severity in workers' compensation programs is anticipated due to a growing workforce participation among Americans aged 75 and older [11][12] Company Strategy and Development Direction - The company is committed to fiscal conservatism, investment in technology, and delivering differentiated results to partners [5] - A strategic focus on deploying AI tools throughout the organization is emphasized, particularly in enhancing communication platforms [5][6] - The company is expanding its employer-focused enterprise comp offering to include new reporting services for better incident tracking and regulatory compliance [17] Management's Comments on Operating Environment and Future Outlook - Management acknowledged that current macroeconomic policies are uncertain but have had minimal direct impact on the markets [4] - The company is well-positioned to navigate economic uncertainty and seize opportunities as they arise [5] - There is a growing demand from payers for solutions that reduce administrative costs and enhance medical loss ratios [12] Other Important Information - The company repurchased 80,661 shares at a total cost of $9 million during the quarter, with a total of 114.5 million shares repurchased to date [19] - The days sales outstanding (DSO) was 41 days, down two days from a year ago [20] - The quarter ending cash balance was $171 million, reflecting a strong and debt-free balance sheet [20] Q&A Session Summary - No specific questions or answers were documented in the provided content, indicating that the call may have concluded without a Q&A segment [22]